Biotest AG: Biotest submits marketing authorisation application for IgG Next Generation and signed first licensing agreement
News: Biotest AG / Key word(s): Miscellaneous
Biotest submits marketing authorisation application for IgG Next Generation and signed first licensing agreement
The marketing authorisation application covers the biochemical-pharmaceutical-technical part, as well as the preclinical and clinical studies in the indications Primary Immunodeficiency Diseases (PID) and chronic Primary Immune Thrombocytopenia (ITP).
"We are very proud that we have managed the balancing act between commissioning a new production facility and dossier preparation for our development product IgG Next Generation so well. Thanks to the tireless efforts and great team spirit of the employees in almost all departments of the company, we managed to realise the submission on schedule at the end of the quarter," said Christine Piasek, responsible Head of Regulatory Affairs / Development Products.
The dossier is now undergoing an assessment process by the authorities. In case of a positive assessment by the authorities, Biotest expects approval in the 4th quarter.
IgG Next Generation is manufactured in an innovative production process and is the main product of the new production facility "Biotest Next Level", which was successfully accepted by the Darmstadt Regional Council in July 2021. This new production facility, which uses state-of-the-art technologies, represents Biotest's increased commitment to the global immunoglobulin market.
Because of the submission, Biotest was able to announce the signature of a licensing agreement for its novel immunoglobulin (IgG Next Generation) with the Saudi Arabian company Pharma Pharmaceutical Industries (PPI).
Based on this agreement and with help of Biotest's immunoglobulin expertise and technology, PPI will be able to introduce in Saudi Arabia the first local polyvalent intravenous immunoglobulin. The agreement is based on an upfront payment for the license, consists of three milestones starting from the contract signature and a 10 years contract manufacturing and supply agreement. Biotest will produce the bulk product in the new BNL fractionation plant. The launch in the Kingdom of Saudi Arabia is expected in 2023.
"This is a historical moment for Biotest as we have signed a contract that is giving immediately the first revenue for our new product coming from our new plant. Moreover, this is the recognition of the quality of our manufacturing process and scientific know-how as well as the confirmation of the importance to expand our product portfolio, our capacity and our commercial network in the immunoglobulin market," said Enrico D'Aiuto, Senior Vice President of Biotest Global Sales & Marketing. "With the signature of this long-term collaboration, we confirm Biotest's historical commercial presence and heritage in the Middle East region and in Saudi Arabia, where Biotest products have been available for years to help the local patient population." "Thanks to PPI's management long-term view, starting from 2023 there will be another therapeutic option available: the first local immunoglobulin, in a period in which we have to face a critical shortage for plasma proteins all over the world due to the impact of COVID-19 on plasma collection" concluded Niklas Rorarius, Regional Director Middle East and Gulf.
About IgG Next Generation
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
|Phone:||0 61 03 - 8 01-0|
|Fax:||0 61 03 - 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1322027|
|End of News||DGAP News Service|